- active not recruitingPHASE2
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
This study looks at a new type of treatment called afamitresgene autoleucel for advanced synovial sarcoma or myxoid liposarcoma. It aims to see how well it works and if it's safe for people who have specific genetic markers.
United States · Canada · France - recruitingPHASE3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
This study is looking at a new medicine called AL3818 (anlotinib) for people with advanced alveolar soft part sarcoma (ASPS). It aims to see how safe and effective it is. Currently, it's only for ASPS patients.
United States · China · Italy - ongoing, recruitingPhase I and Phase II (Integrated)- Bioequivalence Study
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas
This study is looking for adult patients with a certain type of advanced soft tissue sarcoma. It compares a new drug, LB-100, combined with standard doxorubicin treatment, against doxorubicin alone, to see how well it works and if it's safe.
Spain - authorisedHuman Pharmacology (Phase I)- First administration to humans
EPITOME-1015-I: A phase I study to investigate the safety and tolerability of MDG1015 in patients with epithelial ovarian cancer, gastroesophageal adenocarcinoma, round cell liposarcoma and/or synovial sarcoma
This study is testing a new medicine, MDG1015, for the first time in people. It aims to see if it's safe and how well people tolerate it. The study is for certain types of cancer: ovarian, stomach/gullet, and two types of soft tissue sarcoma.
Netherlands